カテゴリ： GlobalData, アメリカ, 企業調査

MedImmune LLC-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：MedImmune LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013526
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：105
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting various diseases. Medimmune undertake research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases. It also develops vaccines for the prevention of infectious diseases. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US.

MedImmune LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12
MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
MedImmune LLC, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
Partnerships 19
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 19
AstraZeneca and MedImmune Expands Agreement with Incyte 20
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 21
Sanofi Enters into Co-Development Agreement with MedImmune 22
MedImmune Enters into Co-Development Agreement with Abpro 23
MedImmune Enters into Agreement with Genisphere 24
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 25
Cepheid, MedImmune and Combacte Enter into Agreement 26
Rani Therapeutics Enters into Agreement with MedImmune 27
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 28
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 29
MedImmune Enters into Research Agreement with University of Sheffield 30
Vall d’Hebron Institute of Oncology Enters into Agreement with AstraZeneca 31
MedImmune Enters into Agreement with Juno Therapeutics 32
MedImmune Enters into Research Agreement with Joslin Diabetes Center 33
MedImmune Enters into Research Agreement with University of Manchester 34
MedImmune Enters into Research Agreement with COEBP 35
MedImmune Enters into Co-Development Agreement with National Cancer Institute 36
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 37
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 38
Cancer Research UK Forms Joint Venture with MedImmune 40
Advaxis Enters into Agreement with MedImmune 41
MedImmune Enters Into Research Agreement With Cambridge University 42
Biolojic Design Enters into Partnership with MedImmune 43
MedImmune Enters Into Research Agreement With Johns Hopkins University 44
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 45
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 46
PeptiDream Enters into Drug Discovery Agreement with MedImmune 47
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 48
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 50
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 51
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 52
AgonOx Enters Into Co-Development Agreement With MedImmune 53
Pfenex Enters Into Collaboration With MedImmune 54
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 55
Licensing Agreements 56
GamaMabs Enters into Licensing Agreement with MedImmune 56
Regeneron Pharma Enters into Licensing Agreement with MedImmune 57
MedImmune Enters into Licensing Agreement with Wacker Biotech 58
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 59
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 60
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 61
MedImmune Enters into Licensing Agreement with Inovio Pharma 62
Kolltan Pharma Enters into Licensing Agreement with Spirogen 63
MedImmune To Enter Into Licensing Agreement With Pfizer 64
Sinovac Biotech Amends Licensing Agreement with MedImmune 65
Shionogi Enters into Licensing Agreement with MedImmune 66
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 67
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 68
Humabs Biomed Enters into Licensing Agreement with MedImmune 70
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 71
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 72
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 73
Spirogen Enters Into Licensing Agreement With Genentech 74
Acquisition 75
MedImmune Acquires Definiens for USD150 Million 75
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 76
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 78
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 79
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 80
MedImmune LLC – Key Competitors 81
MedImmune LLC – Key Employees 82
MedImmune LLC – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Recent Developments 85
Government and Public Interest 85
Jul 06, 2017: New Synthetic DNA-Based Strategy Shows Promise Against a Diverse Range of Influenza Viruses 85
Product News 86
11/14/2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 86
Aug 23, 2016: IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer’s Disease 87
07/21/2016: New Study Presents Groundbreaking Pre-clinical work in Developing Immune Therapy 88
Apr 22, 2016: AstraZeneca launches integrated genomics approach to transform drug discovery and development 89
Product Approvals 91
Mar 29, 2017: AstraZenecas potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe 91
Oct 27, 2016: AstraZeneca head and neck cancer trials 92
Mar 09, 2016: AstraZeneca’s potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation 93
Mar 07, 2016: Medimmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A 94
Clinical Trials 95
Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria 95
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer 96
Jan 18, 2017: Novel Anti-IL-6 Antibody for Rheumatoid Arthritis from WuXi–MedImmune Joint Venture Receives Clinical Trial Permit from CFDA 97
Nov 22, 2016: AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold 98
Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke’s launches clinical trial of cancer combination therapy 99
Apr 15, 2016: Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma 100
Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 101
Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt 102
Feb 08, 2016: Astrazeneca’S Combination Of Durvalumab With Tremelimumab Shows Clinical Activity In Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status 103
Appendix 105
Methodology 105
About GlobalData 105
Contact Us 105
Disclaimer 105

List of Tables
MedImmune LLC, Pharmaceuticals & Healthcare, Key Facts 2
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
MedImmune LLC, Deals By Therapy Area, 2011 to YTD 2017 11
MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12
MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
ADC Therapeutics To Raise US$50 Million In Venture Financing 17
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 19
AstraZeneca and MedImmune Expands Agreement with Incyte 20
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 21
Sanofi Enters into Co-Development Agreement with MedImmune 22
MedImmune Enters into Co-Development Agreement with Abpro 23
MedImmune Enters into Agreement with Genisphere 24
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 25
Cepheid, MedImmune and Combacte Enter into Agreement 26
Rani Therapeutics Enters into Agreement with MedImmune 27
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 28
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 29
MedImmune Enters into Research Agreement with University of Sheffield 30
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 31
MedImmune Enters into Agreement with Juno Therapeutics 32
MedImmune Enters into Research Agreement with Joslin Diabetes Center 33
MedImmune Enters into Research Agreement with University of Manchester 34
MedImmune Enters into Research Agreement with COEBP 35
MedImmune Enters into Co-Development Agreement with National Cancer Institute 36
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 37
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 38
Cancer Research UK Forms Joint Venture with MedImmune 40
Advaxis Enters into Agreement with MedImmune 41
MedImmune Enters Into Research Agreement With Cambridge University 42
Biolojic Design Enters into Partnership with MedImmune 43
MedImmune Enters Into Research Agreement With Johns Hopkins University 44
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 45
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 46
PeptiDream Enters into Drug Discovery Agreement with MedImmune 47
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 48
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 50
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 51
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 52
AgonOx Enters Into Co-Development Agreement With MedImmune 53
Pfenex Enters Into Collaboration With MedImmune 54
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 55
GamaMabs Enters into Licensing Agreement with MedImmune 56
Regeneron Pharma Enters into Licensing Agreement with MedImmune 57
MedImmune Enters into Licensing Agreement with Wacker Biotech 58
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 59
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 60
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 61
MedImmune Enters into Licensing Agreement with Inovio Pharma 62
Kolltan Pharma Enters into Licensing Agreement with Spirogen 63
MedImmune To Enter Into Licensing Agreement With Pfizer 64
Sinovac Biotech Amends Licensing Agreement with MedImmune 65
Shionogi Enters into Licensing Agreement with MedImmune 66
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 67
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 68
Humabs Biomed Enters into Licensing Agreement with MedImmune 70
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 71
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 72
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 73
Spirogen Enters Into Licensing Agreement With Genentech 74
MedImmune Acquires Definiens for USD150 Million 75
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 76
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 78
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 79
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 80
MedImmune LLC, Key Competitors 81
MedImmune LLC, Key Employees 82
MedImmune LLC, Other Locations 83
MedImmune LLC, Subsidiaries 84

★海外企業調査レポート[MedImmune LLC-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • DesignMedix Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases such as malaria and diarrhea. The company develops malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. It develops DM1157, a drug candidate that pro …
  • Synthos SA：企業の戦略的SWOT分析
    Synthos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Pluspetrol SA：石油・ガス：M&Aディール及び事業提携情報
    Summary Pluspetrol SA (Pluspetrol), a subsidiary of Pluspetrol Resources Corporation N.V. is an oil and gas company that produces oil and gas products. The company’s products include LPG, natural gas, crude oil, liquid fuel, liquid gas and others. It explores and develops oil and gas reserves based …
  • Impel NeuroPharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delive …
  • Eagle Plains Resources Ltd (EPL)：企業の財務・戦略的SWOT分析
    Summary Eagle Plains Resources Ltd (Eagle Plains) operates as a mining and mineral exploration and mine development company that offers mineral resources. The company offers acquisition, exploration, mining, operations, management, production, and development gold, base metals, rare earth elements, …
  • S.C. Hidroelectrica SA：企業の戦略的SWOT分析
    S.C. Hidroelectrica SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • JGC Holdings Corp (1963)
    JGC Holdings Corp (1963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Koninklijke Philips N.V. (PHIA)：医療機器：M&Aディール及び事業提携情報
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company develops and manufactures medical systems, consumer electronics and lighting products. The company offers patient care & clinical informatics, imaging systems, healthcare transformation services and home healthcare soluti …
  • Daiichi Sankyo Co Ltd (4568)：製薬・医療：M&Aディール及び事業提携情報
    Summary Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompa …
  • Eli Lilly and Co (LLY)-医療機器分野：企業M&A・提携分析
    Summary Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men's health and musculoskeletal problems. It a …
  • Biotec Pharmacon ASA (BIOTEC)：医療機器：M&Aディール及び事業提携情報
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Care UK Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Care UK Ltd (Care UK) is a healthcare service provider that offers clinical and social care services. The company’s healthcare services include treatment centres, General Practitioner(GP) practices, NHS walk-in centres, GP out-of-hours, prison health services, clinical assessment, diagnostic …
  • African Development Bank Group：企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Magnis Energy Technologies Ltd (MNS)：企業の財務・戦略的SWOT分析
    Magnis Energy Technologies Ltd (MNS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Prairie Farms Dairy Inc：企業の戦略・SWOT・財務情報
    Prairie Farms Dairy Inc - Strategy, SWOT and Corporate Finance Report Summary Prairie Farms Dairy Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Kitoku Shinryo Co., Ltd.：企業の戦略・SWOT・財務情報
    Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Jyske Bank A/S：企業の戦略・SWOT・財務情報
    Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report Summary Jyske Bank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Indigo Books & Music, Inc.：戦略・SWOT・企業財務分析
    Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report Summary Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Littelfuse, Inc.：企業のM&A・事業提携・投資動向
    Littelfuse, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Littelfuse, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Tommy Hilfiger Licensing LLC：企業の戦略・SWOT・財務情報
    Tommy Hilfiger Licensing LLC - Strategy, SWOT and Corporate Finance Report Summary Tommy Hilfiger Licensing LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆